Login to Your Account

Cytos Shares Plunge as Vaccine Trial Misses Main Endpoint

By Cormac Sheridan

Wednesday, October 21, 2009
Cytos Biotechnology AG lost almost one-third of its value Friday on news that its therapeutic vaccine for nicotine addiction failed to show efficacy in a Phase II study. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription